| scholarly article | Q13442814 |
| P50 | author | Sutee Yoksan | Q114411207 |
| Sirijitt Vasanawathana | Q115124446 | ||
| Wannee Limpitikul | Q115124448 | ||
| Pojchong Chotiyarnwong | Q57306444 | ||
| Juthathip Mongkolsapaya | Q59593587 | ||
| Jonathan Grimes | Q60680498 | ||
| Prida Malasit | Q114399357 | ||
| Bridget Wills | Q30112202 | ||
| Cameron P. Simmons | Q37392993 | ||
| Gavin R Screaton | Q42305839 | ||
| P2093 | author name string | Claire M Midgley | |
| Hai Bac Tran | |||
| Aleksandra Flanagan | |||
| Emily Waiyaiya | |||
| Martha Bajwa-Joseph | |||
| Alison E Cowper | |||
| Pojchong Chotiyarnwon | |||
| P2860 | cites work | Original antigenic sin in dengue | Q24570059 |
| Rapid cloning of high-affinity human monoclonal antibodies against influenza virus | Q24644672 | ||
| Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention | Q24684689 | ||
| Structure of dengue virus: implications for flavivirus organization, maturation, and fusion | Q24736810 | ||
| Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered | Q24736974 | ||
| Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification | Q27315772 | ||
| Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells | Q27469935 | ||
| Serological differentiation of infections with dengue virus serotypes 1 to 4 by using recombinant antigens | Q27473050 | ||
| Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus | Q27473186 | ||
| West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody | Q27477479 | ||
| A ligand-binding pocket in the dengue virus envelope glycoprotein | Q27477685 | ||
| Solution structure of the envelope protein domain III of dengue-4 virus | Q27480990 | ||
| Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes | Q27485031 | ||
| Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody | Q27485050 | ||
| Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II | Q27486409 | ||
| Characterization of Dengue Virus Complex-Specific Neutralizing Epitopes on Envelope Protein Domain III of Dengue 2 Virus | Q27486788 | ||
| Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens | Q27488243 | ||
| Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody | Q27489654 | ||
| A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model | Q27490166 | ||
| Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses | Q27491299 | ||
| The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1 | Q27491317 | ||
| Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins | Q27649830 | ||
| Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity | Q27860703 | ||
| The global emergence/resurgence of arboviral diseases as public health problems | Q29616270 | ||
| Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein | Q29618169 | ||
| Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: effects of aging and "original antigenic sin" | Q72389005 | ||
| Original antigenic sin: experiments with a defined antigen | Q72650525 | ||
| Original antigenic sin in ferrets: the response to sequential infections with influenza viruses | Q72805503 | ||
| Influenza: the new acquayantance | Q73246780 | ||
| Monoclonal Antibody Mapping of the Envelope Glycoprotein of the Dengue 2 Virus, Jamaica | Q29618177 | ||
| Research on dengue during World War II | Q29619423 | ||
| Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever | Q29619530 | ||
| Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever | Q29619585 | ||
| Prospects for a dengue virus vaccine | Q29619608 | ||
| In Vivo Enhancement of Dengue Virus Infection in Rhesus Monkeys by Passively Transferred Antibody | Q29619712 | ||
| Evidence That Maternal Dengue Antibodies Are Important in the Development of Dengue Hemorrhagic Fever in Infants | Q29620637 | ||
| Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. | Q34120070 | ||
| An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells | Q34552933 | ||
| Original antigenic sin responses to influenza viruses | Q34995177 | ||
| Progress towards a dengue vaccine | Q35009119 | ||
| Maternal antibody and viral factors in the pathogenesis of dengue virus in infants | Q35097469 | ||
| Disquisitions on Original Antigenic Sin. II. Proof in lower creatures | Q36268260 | ||
| Disquisitions of Original Antigenic Sin. I. Evidence in man | Q36268293 | ||
| Immunopathological mechanisms in dengue and dengue hemorrhagic fever | Q36581319 | ||
| Dengue hemorrhagic Fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. | Q38871276 | ||
| Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins | Q38905838 | ||
| Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus | Q39097395 | ||
| Immunological comparison of azurins of known amino acid sequence. Dependence of cross-reactivity upon sequence resemblance | Q39354298 | ||
| Genotype-specific neutralization and protection by antibodies against dengue virus type 3. | Q39668466 | ||
| Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III. | Q39707252 | ||
| The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry | Q39780069 | ||
| On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes | Q39876628 | ||
| Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. | Q40401609 | ||
| Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells | Q40411324 | ||
| Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus | Q40441111 | ||
| Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice | Q40492701 | ||
| Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand | Q40539101 | ||
| Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. | Q40597816 | ||
| Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism | Q40599604 | ||
| The micro-focus reduction neutralization test for determining dengue and Japanese encephalitis neutralizing antibodies in volunteers vaccinated against dengue | Q40642157 | ||
| Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence | Q40662346 | ||
| Rapid detection and identification of dengue viruses by polymerase chain reaction (PCR) | Q40667226 | ||
| Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection | Q40680439 | ||
| Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. | Q40698415 | ||
| Use of 'original antigenic sin' theory to determine the serotypes of previous dengue infections | Q40722761 | ||
| Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection | Q40798801 | ||
| Genetic relationships of the dengue virus serotypes | Q40817835 | ||
| Antibody-enhanced dengue virus infection in primate leukocytes | Q40884212 | ||
| Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus | Q41874514 | ||
| Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice | Q42988087 | ||
| Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination | Q45521991 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Dengue virus | Q476209 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 410-21 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | An in-depth analysis of original antigenic sin in dengue virus infection | |
| P478 | volume | 85 |
| Q28954730 | A Rapid Zika Diagnostic Assay to Measure Neutralizing Antibodies in Patients |
| Q66679537 | A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III |
| Q36667964 | An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection |
| Q37987131 | Animal Models of Dengue Virus Infection |
| Q36931818 | Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo |
| Q38157718 | Antibody-based assay discriminates Zika virus infection from other flaviviruses |
| Q35669397 | Antigenic cooperation among intrahost HCV variants organized into a complex network of cross-immunoreactivity |
| Q28730914 | Assessing the potential of a candidate dengue vaccine with mathematical modeling |
| Q36487320 | Association between magnitude of the virus-specific plasmablast response and disease severity in dengue patients |
| Q36950883 | B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts |
| Q35791624 | B-Cell Responses to Human Bocaviruses 1-4: New Insights from a Childhood Follow-Up Study |
| Q35567408 | B-cell responses during primary and secondary dengue virus infections in humans |
| Q95628083 | Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein |
| Q38121757 | Challenges for the formulation of a universal vaccine against dengue. |
| Q57464788 | Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus |
| Q35220195 | Clinical outcome and genetic differences within a monophyletic Dengue virus type 2 population |
| Q30361791 | Consultation on dengue vaccines: progress in understanding protection, 26-28 June 2013, Rockville, Maryland. |
| Q38016235 | Controversies in dengue pathogenesis |
| Q34779065 | Correlation between Dengue-Specific Neutralizing Antibodies and Serum Avidity in Primary and Secondary Dengue Virus 3 Natural Infections in Humans |
| Q34354665 | Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins |
| Q33408300 | Current progress in dengue vaccines |
| Q58541683 | Dengue Virus IgM Serotyping by ELISA with Recombinant Mutant Envelope Proteins |
| Q37663001 | Dengue in renal transplant recipients: Clinical course and impact on renal function |
| Q36286276 | Dengue virus antibody database: Systematically linking serotype-specificity with epitope mapping in dengue virus |
| Q34184747 | Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcγR-expressing cells |
| Q39432395 | Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection |
| Q59352698 | Dengue: a growing threat requiring vaccine development for disease prevention |
| Q35081258 | Detection of serotype-specific antibodies to the four dengue viruses using an immune complex binding (ICB) ELISA |
| Q40135692 | Development and Evaluation of a SYBR Green-Based Real-Time Multiplex RT-PCR Assay for Simultaneous Detection and Serotyping of Dengue and Chikungunya Viruses |
| Q34408025 | Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus |
| Q35842365 | Dominant Cross-Reactive B Cell Response during Secondary Acute Dengue Virus Infection in Humans |
| Q40294304 | Enhanced humoral and HLA‐A2‐restricted dengue virus‐specific T‐cell responses in humanized BLT NSG mice |
| Q40244711 | Evaluation and analysis of dengue virus enhancing and neutralizing activities using simple high-throughput assays |
| Q39039111 | Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response. |
| Q40225317 | Evaluation of the European tick-borne encephalitis vaccine against Omsk hemorrhagic fever virus |
| Q24737461 | Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex |
| Q35601805 | Functionality of dengue virus specific memory T cell responses in individuals who were hospitalized or who had mild or subclinical dengue infection |
| Q39126155 | Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage. |
| Q36172100 | Genome-wide patterns of intrahuman dengue virus diversity reveal associations with viral phylogenetic clade and interhost diversity |
| Q35665847 | High-resolution analysis of intrahost genetic diversity in dengue virus serotype 1 infection identifies mixed infections |
| Q64107709 | Higher levels of B-cell mutation in the early germinal centres of an inefficient secondary antibody response to a variant influenza haemagglutinin |
| Q37995555 | Human poly- and cross-reactive anti-viral antibodies and their impact on protection and pathology |
| Q29994510 | Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology |
| Q37901360 | Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms |
| Q33867337 | In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers |
| Q36363799 | Infectious dengue vesicles derived from CD61+ cells in acute patient plasma exhibited a diaphanous appearance |
| Q40124689 | Influence of FcγRIIa-Expressing Cells on the Assessment of Neutralizing and Enhancing Serum Antibodies Elicited by a Live-Attenuated Tetravalent Dengue Vaccine |
| Q36619335 | Insights into the molecular evolution of Dengue virus type 4 in Puerto Rico over two decades of emergence |
| Q37336555 | Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge |
| Q91649517 | Local immunodeficiency: Minimal networks and stability |
| Q30392050 | Low levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients |
| Q36616521 | Lower IgG somatic hypermutation rates during acute dengue virus infection is compatible with a germinal center-independent B cell response. |
| Q36026321 | Modelling Virus and Antibody Dynamics during Dengue Virus Infection Suggests a Role for Antibody in Virus Clearance |
| Q38878831 | Modelling original antigenic sin in dengue viral infection |
| Q38045381 | Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans |
| Q37082976 | Neonatal Bacillus Calmette-Guérin vaccination alleviates lipopolysaccharide-induced neurobehavioral impairments and neuroinflammation in adult mice |
| Q36694134 | Network Analysis of the Chronic Hepatitis C Virome Defines Hypervariable Region 1 Evolutionary Phenotypes in the Context of Humoral Immune Responses |
| Q50099498 | Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein |
| Q38646923 | New insights into the immunopathology and control of dengue virus infection |
| Q90640026 | Oligomeric state of the ZIKV E protein defines protective immune responses |
| Q38097613 | On the benefits of sin: can greater understanding of the 1F7-idiotypic repertoire freeze enhance HIV vaccine development? |
| Q45323856 | Peptides as Therapeutic Agents for Dengue Virus |
| Q34226542 | Phage display approaches for the isolation of monoclonal antibodies against dengue virus envelope domain III from human and mouse derived libraries. |
| Q37363501 | Plasmablasts During Acute Dengue Infection Represent a Small Subset of a Broader Virus-specific Memory B Cell Pool |
| Q37723038 | Polytopic vaccination with a live-attenuated dengue vaccine enhances B-cell and T-cell activation, but not neutralizing antibodies |
| Q24289014 | Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections |
| Q38794583 | Progress towards understanding the pathogenesis of dengue hemorrhagic fever. |
| Q39434858 | Protection from Secondary Dengue Virus Infection in a Mouse Model Reveals the Role of Serotype Cross-Reactive B and T Cells |
| Q38731663 | Protective and immunological behavior of chimeric yellow fever dengue vaccine |
| Q57061690 | Quantification of dengue virus specific T cell responses and correlation with viral load and clinical disease severity in acute dengue infection |
| Q35235314 | Quantifying the emergence of dengue in Hanoi, Vietnam: 1998-2009. |
| Q27330166 | Randomized controlled ferret study to assess the direct impact of 2008-09 trivalent inactivated influenza vaccine on A(H1N1)pdm09 disease risk |
| Q26766156 | Recent advances in understanding dengue |
| Q40298293 | Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera |
| Q98164941 | Sequential immunization induces strong and broad immunity against all four dengue virus serotypes |
| Q66678780 | Serological inference of past primary and secondary dengue infection: implications for vaccination |
| Q34496118 | Seroprevalence of neutralizing antibodies against dengue virus in two localities in the state of Morelos, Mexico |
| Q47208514 | Spatial and temporal patterns of dengue infections in Timor-Leste, 2005-2013. |
| Q57940620 | Stratified sero-prevalence revealed overall high disease burden of dengue but suboptimal immunity in younger age groups in Pune, India |
| Q27678419 | Structural Analysis of a Dengue Cross-Reactive Antibody Complexed with Envelope Domain III Reveals the Molecular Basis of Cross-Reactivity |
| Q33414560 | Subversion of early innate antiviral responses during antibody-dependent enhancement of Dengue virus infection induces severe disease in immunocompetent mice |
| Q26995782 | The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response |
| Q37987124 | The Human Antibody Response to Dengue Virus Infection |
| Q33817714 | The Role of Heterotypic DENV-specific CD8+T Lymphocytes in an Immunocompetent Mouse Model of Secondary Dengue Virus Infection |
| Q35236379 | The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2. |
| Q35496004 | The role of pre-existing cross-reactive antibodies in determining the efficacy of vaccination in humans: study protocol for a randomized controlled trial |
| Q27681306 | The structural basis for serotype-specific neutralization of dengue virus by a human antibody |
| Q34607919 | Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. |
| Q88872577 | Vaccination-induced herd immunity: Successes and challenges |
| Q28077521 | Vaccines and immunization strategies for dengue prevention |
| Q39172722 | Vaccines licensed and in clinical trials for the prevention of dengue |
| Q88343676 | What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? A Role for Antibody Feedback |
| Q84957860 | Zika seroprevalence declines and neutralizing antibodies wane in adults following outbreaks in French Polynesia and Fiji |
| Q38156674 | Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors. |
Search more.